CureVac N.V is a biotechnology business based in the US. CureVac N-V shares (CVAC) are listed on the NASDAQ and all prices are listed in US Dollars. CureVac N-V employs 455 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in CureVac N-V
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CVAC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
CureVac N-V stock price (NASDAQ: CVAC)Use our graph to track the performance of CVAC stocks over time.
CureVac N-V shares at a glance
|Latest market close||$111.48|
|52-week range||$36.15 - $151.80|
|50-day moving average||$66.90|
|200-day moving average||$93.12|
|Wall St. target price||$67.47|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy CureVac N-V shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CureVac N-V stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CureVac N-V price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||72.14%|
|3 months (2021-04-30)||-4.67%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
CureVac N-V financials
|Revenue TTM||$48.9 million|
|Gross profit TTM||$34.7 million|
|Return on assets TTM||-10.17%|
|Return on equity TTM||-38.63%|
|Market capitalisation||$9.8 billion|
TTM: trailing 12 months
Shorting CureVac N-V shares
There are currently 3.6 million CureVac N-V shares held short by investors – that's known as CureVac N-V's "short interest". This figure is 12.9% down from 4.2 million last month.
There are a few different ways that this level of interest in shorting CureVac N-V shares can be evaluated.
CureVac N-V's "short interest ratio" (SIR)
CureVac N-V's "short interest ratio" (SIR) is the quantity of CureVac N-V shares currently shorted divided by the average quantity of CureVac N-V shares traded daily (recently around 2.3 million). CureVac N-V's SIR currently stands at 1.58. In other words for every 100,000 CureVac N-V shares traded daily on the market, roughly 1580 shares are currently held short.
However CureVac N-V's short interest can also be evaluated against the total number of CureVac N-V shares, or, against the total number of tradable CureVac N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CureVac N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CureVac N-V shares in existence, roughly 20 shares are currently held short) or 0.045% of the tradable shares (for every 100,000 tradable CureVac N-V shares, roughly 45 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CureVac N-V.
Find out more about how you can short CureVac N-V stock.
CureVac N-V share dividends
We're not expecting CureVac N-V to pay a dividend over the next 12 months.
CureVac N-V overview
CureVac N. V. , a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Stocks similar to CureVac N-V
CureVac N-V in the news
Biotech Bonanza: Promising Second Half Outlook
‘The race is on’: CureVac seeks answers to vaccine disappointment
Novartis CEO says Covid-related doctor visit delays likely impacting cancer diagnosis rates
Frequently asked questionsWhat percentage of CureVac N-V is owned by insiders or institutions?
Currently 55.921% of CureVac N-V shares are held by insiders and 23.469% by institutions. How many people work for CureVac N-V?
Latest data suggests 455 work at CureVac N-V. When does the fiscal year end for CureVac N-V?
CureVac N-V's fiscal year ends in December. Where is CureVac N-V based?
CureVac N-V's address is: Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076 What is CureVac N-V's ISIN number?
CureVac N-V's international securities identification number is: NL0015436031
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert